Volunteer recruitment begins
The Marqués de Valdecilla University Hospital is participating in a study investigating a seasonal influenza vaccine based on messenger RNA (mRNA) technology (already used in the development of authorised vaccines for other diseases, such as respiratory syncytial virus infection, COVID-19 and influenza itself) in adults aged 65 and over.
This trial will be conducted internationally over the coming weeks, and in Cantabria it will involve the Valdecilla Clinical Trials Unit. Its implementation requires the recruitment of 100 volunteers in our region.
In accordance with international standards, the trial has received the required authorisation from the Spanish Agency for Medicines and Medical Devices (AEMPS), under the Spanish Ministry of Health, and has been evaluated and approved by a national Research Ethics Committee for Medicinal Products.
The aim of this study is to assess clinical efficacy and immune response, as well as safety, by comparing the investigational vaccine with an already authorised influenza vaccine.
Information for volunteers
Vaccines are biological preparations capable of generating immunity against a disease by stimulating the production of antibodies within the body.
This process stimulates the immune system so that it can subsequently recognise the pathogen as a threat and destroy it, after generating what is known as “immunological memory”. Vaccines are used prophylactically to prevent future infections or reduce their severity.
Why are we conducting this study?
Uncomplicated influenza is characterised by the sudden onset of general and respiratory symptoms that usually resolve within a week. However, in vulnerable populations such as older adults, it can aggravate underlying medical conditions and potentially cause life-threatening complications.
Annual influenza vaccination is currently the most effective strategy for preventing complications and associated mortality. Influenza viruses constantly modify their structure, allowing them to evade pre-existing immunity, and seasonal influenza vaccines must therefore be reformulated and administered annually. In addition, the effectiveness of these vaccines has historically been suboptimal (10% in years when the vaccine and circulating virus strains do not match, and a maximum of 60%). Therefore, new technologies are needed to improve the immunogenicity of influenza vaccines.
If you are 65 years of age or older, are a healthy person or have a chronic condition that is well controlled, and have not yet received the influenza vaccine this autumn 2026, you may participate in this study.
If you or someone you know would like more information about this investigational vaccine or is interested in participating in this study, please contact a member of the research team using the following contact details:
NAME: BLANCA SANCHEZ
TELEPHONE: 942 204084
DEPARTMENT: CLINICAL TRIALS UNIT. CLINICAL PHARMACOLOGY DEPARTMENT. MARQUÉS DE VALDECILLA UNIVERSITY HOSPITAL
FLOOR: PAVILION 15 – 2ND FLOOR
